ProKidney Corp. Cash Flow Conversion Efficiency
ProKidney Corp. cash flow conversion efficiency. Based on the latest financial reports, ProKidney Corp. (PROK) has a cash flow conversion efficiency ratio of -0.181x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.37 Million) by net assets ($222.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ProKidney Corp. (2019–2025)
Cash flow conversion efficiency of ProKidney Corp. from 2019 to 2025. This chart illustrates how ProKidney Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest ProKidney Corp. stock price today for real-time trading data and today's change.
ProKidney Corp. Cash Flow Conversion Ratio Explained
ProKidney Corp. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ProKidney Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ProKidney Corp. ranked by their cash flow conversion efficiency. Also see PROK company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anhui Fuhuang Steel Structure Co Ltd
SHE:002743
|
-0.012x |
|
Baoding Dongli Machinery Co.Ltd.
SHE:301298
|
N/A |
|
Ningbo GQY Video Telecom
SHE:300076
|
-0.014x |
|
Arlandastad Group AB
ST:AGROUP
|
0.001x |
|
Hy-Lok Corporation
KQ:013030
|
0.028x |
|
Xxentria Technology Materials Co Ltd
TWO:8942
|
0.008x |
|
Zumiez Inc
NASDAQ:ZUMZ
|
0.018x |
|
ADAGENE INC. SP.ADR
F:978
|
N/A |
Annual Cash Flow Conversion Efficiency for ProKidney Corp. (2019–2025)
The table below shows the annual cash flow conversion efficiency of ProKidney Corp. from 2019 to 2025. Review PROK financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $300.79 Million | $-120.12 Million | -0.399x | -26.94% |
| 2024-12-31 | $401.64 Million | $-126.35 Million | -0.315x | -36.68% |
| 2023-12-31 | $391.34 Million | $-90.07 Million | -0.230x | -50.76% |
| 2022-12-31 | $504.94 Million | $-77.09 Million | -0.153x | +91.83% |
| 2021-12-31 | $26.92 Million | $-50.30 Million | -1.869x | +26.80% |
| 2020-12-31 | $9.86 Million | $-25.18 Million | -2.553x | -52690.69% |
| 2019-12-31 | $15.88 Million | $-76.81K | -0.005x | -- |
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the devel… Read more